TL;DR
CJC-1295 (with DAC) and Ipamorelin are two investigational peptide secretagogues targeting the GH axis through distinct non-overlapping receptors — CJC-1295 activates the GHRH receptor on pituitary somatotrophs; Ipamorelin activates the ghrelin receptor (GHSR-1a). The combination stack has zero published human trials. Both compounds raise GH and IGF-1 individually in small healthy-adult PK/PD studies, but no trial has tested the stack for body composition, strength, recovery, sleep, or anti-aging outcomes. Neither is FDA-approved. Both are WADA-prohibited. Anti-aging and performance claims are unsubstantiated.
Why It Matters for Vitals
Vitals users exploring peptide protocols need an accurate evidence boundary for this stack:
- GH/IGF-1 biomarkers are directly measurable — IGF-1 trajectory is the most actionable wearable-adjacent endpoint
- Wearable indirect signals are not validated for stack response — no CJC/Ipa-specific HRV, sleep staging, or recovery algorithm exists
- Users may already be on this stack — Vitals should be able to provide safety monitoring guidance (IGF-1, fasting glucose, lipids) without validating the stack as effective
- Key numbers to preserve: GH 2–10× baseline, IGF-1 1.5–3× baseline, 7.5-fold basal/trough GH rise under DAC exposure [PMID:16352683, PMID:17018654]
- Anti-aging claims are contested — IGF-1 elevation shows U-shaped mortality association; pushing IGF-1 above age-adjusted normal is not an unqualified wellness target [PMID:37066827]
Key Facts
| Combination human trials | Zero — no published or registered trial of the stack for any endpoint |
| CJC-1295 human evidence | Phase I/II RCT, n=27 healthy adults; GH 2–10× baseline ≥6 days; IGF-1 1.5–3× baseline 9–11 days [PMID:16352683] |
| Ipamorelin human evidence | PK/PD study, n=40 healthy males, IV infusion; GH peaked ~0.67h; Phase II postoperative ileus trial negative [PMID:10496658, PMID:25331030] |
| CJC-1295 half-life (with DAC) | ~5.8–8.1 days SC [PMID:16352683] |
| Ipamorelin half-life (IV) | ~2.0 hours [PMID:10496658]; SC bioavailability in humans not reported |
| CJC-1295 without DAC half-life | Unverified — no primary human PK study located; commonly cited ~30 min is not in primary literature |
| GH pulse preservation | Frequency and amplitude preserved under CJC-1295 DAC; basal/trough GH rose 7.5-fold [PMID:17018654] |
| WADA status | Both prohibited at all times — no TUE pathway for this use |
| FDA status | Not approved; regulatory status in transition (US) |
| Development status | Both programs discontinued; no active sponsor or IND |
Mechanism Summary
CJC-1295 — GHRH Receptor Pathway
CJC-1295 is a tetrasubstituted GHRH(1-29) analog with a Drug Affinity Complex (DAC) linker that covalently binds serum albumin at Cys34, creating a circulating reservoir with ~6–8 day terminal half-life [PMID:15817669].
CJC-1295 → GHRH receptor → Gs/cAMP/PKA/CREB/Pit-1 → GH gene transcription + granule release
→ Hepatic/peripheral IGF-1 production
Key effects: dose-dependent GH elevation (2–10× baseline ≥6 days); IGF-1 elevation (1.5–3× baseline 9–11 days); basal/trough GH rises 7.5-fold between pulses [PMID:17018654].
Ipamorelin — GHSR-1a Pathway
Ipamorelin (NNC 26-0161) is a pentapeptide selective GHSR-1a agonist. In swine, it did not elevate ACTH or cortisol at >200× its GH ED50 — the primary basis for its claimed selectivity over earlier GHRPs [PMID:9849822]. Human endocrine selectivity is not established in dedicated studies.
Ipamorelin → GHSR-1a → Ca²⁺/PKC + hypothalamic somatostatin modulation → acute GH exocytosis
Human data: single GH pulse peaks at ~0.67 hours post-IV dose; terminal half-life ~2 hours [PMID:10496658].
Dual-Pathway Synergy (Class-Level Evidence Only)
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Target | GHRH receptor | GHSR-1a (ghrelin receptor) |
| Signaling | Gs/cAMP/PKA | Ca²⁺/PKC + somatostatin modulation |
| Location | Anterior pituitary somatotrophs | Anterior pituitary + arcuate hypothalamus |
GHRH + GHRP synergy is established in humans: combined submaximal GHRP + GHRH produces GH responses greater than either pathway alone [PMID:2108187, PMID:11549707, PMID:15126555]. This has never been demonstrated for the specific CJC-1295 + Ipamorelin combination.
Tachyphylaxis
GHSR-1a agonists produce homologous receptor desensitization: continuous agonist binding causes GHSR-1a internalization with slow recycling (~360 min in vitro) [PMID:14576181]. In humans, continuous GHRP infusion attenuates the GH response to subsequent GHRP bolus while enhancing GHRH response [PMID:8496311]. Twice-daily hexarelin for 16 weeks showed reversible partial attenuation [PMID:10990150]. Twice-daily ipamorelin is expected to produce similar desensitization.
CJC-1295 DAC’s continuous exposure may also drive GHRH receptor desensitization (documented in vitro) [PMID:11169166]; human data absent.
What the Current Evidence Suggests
Individual Compounds — Confirmed PK/PD
- CJC-1295 with DAC reliably elevates GH and IGF-1 in healthy adults for 6–11 days after a single SC dose [PMID:16352683]
- Ipamorelin produces selective acute GH stimulation in humans [PMID:10496658]; its Phase II postoperative ileus trial was negative for efficacy [PMID:25331030]
Combination Stack — Zero Human Trials
⚠️ No published or registered clinical trial has evaluated CJC-1295 + Ipamorelin in combination for any endpoint. All synergy claims, body composition claims, and performance claims for the combined stack are extrapolated from class-level physiology and have no direct evidentiary support.
Body Composition and Performance
The most relevant systematic review found that recombinant GH in healthy physically fit adults produced ~2.1 kg lean mass increase but no improvement in strength or VO2max; soft-tissue edema and fatigue were common [PMID:18347346]. No trial has demonstrated that CJC-1295, Ipamorelin, or their combination improves strength, athletic performance, or body composition in healthy adults.
Anti-Aging Claims
Contested. Systematic reviews of GH/GHS in older adults show modest body composition changes, increased adverse effects, and no proven anti-aging outcomes [PMID:17227934, PMID:19174493]. High IGF-1 is associated with higher breast/prostate cancer risk (observational) and shows U-shaped mortality association [PMID:37066827]. No prospective controlled trial has demonstrated anti-aging efficacy for the stack.
Tesamorelin Comparison
Tesamorelin (TH9507) is the only secretagogue-class compound with FDA approval (HIV-associated lipodystrophy) and clinical body composition endpoints (−15.4% VAT reduction at 26 weeks in 806 HIV patients) [PMID:20554713]. This does not validate the CJC-1295/Ipamorelin stack; the indication and population are specific.
Likely Wearable / Vitals Relevance
What Vitals CAN Monitor (Caveats Apply)
| Signal | Rationale | Caveat |
|---|---|---|
| IGF-1 trajectory | Primary GH-axis exposure marker; elevated 1.5–3× baseline in trials | Not proof of net benefit; interpret against age-adjusted ranges |
| Fasting glucose / HbA1c | GH antagonizes insulin; glucose intolerance risk | Direction uncertain; monitoring warranted especially in at-risk populations |
| Body composition (DEXA) | IGF-1 is anabolic; lean mass may increase | Changes may reflect fluid retention; BIA insufficiently precise |
| HRV / RHR / readiness | Downstream recovery context | Not GH-axis response markers; no stack-specific validation |
| Sleep architecture | GH pulses linked to SWS physiology | Consumer sleep staging not precise enough for endocrine endpoints |
What Vitals SHOULD NOT Do
- Do not operationalize wearable-only detection of stack use
- Do not infer dose, formulation (DAC vs. no-DAC), or desensitization state from Vitals data
- Do not recommend dose changes or stop/continue decisions from Vitals algorithms
- Do not treat IGF-1 elevation as proof of net benefit
- Do not represent Vitals as a peptide-optimization or anti-doping detection platform
Pre-Use Baseline Recommendation
Collect 2–4 weeks of stable baseline before initiating: sleep duration/efficiency, resting HR, nocturnal HRV, fasting glucose, IGF-1, lipid panel, DEXA (same method/conditions). Compare within-person over time; do not use population-level peptide claims as benchmarks.
Risks and Uncertainty
Known Adverse Events (from small short-term trials)
CJC-1295 [PMID:16352683]: injection site reactions, headache, transient water retention, diarrhea, flushing, arthralgia, fatigue, paresthesia.
Ipamorelin [PMID:9849822, PMID:25331030]: generally well-tolerated in short IV setting; headache reported.
One fatal event: CJC-1295-with-DAC Phase II trial (NCT00267527, HIV patients) terminated after one participant died of acute MI ~2h after the 11th weekly injection; attributed to pre-existing CAD; no formal causality assessment completed.
Serious Theoretical Risks
- IGF-1 and cancer: IGF-1 is a known mitogen; elevated IGF-1 linked to breast/prostate cancer risk (observational); causality not established but prospective data absent [PMID:37066827]
- Cardiovascular: GH excess causes cardiac hypertrophy, arrhythmias, hypertension; no prospective cardiovascular outcome data for either compound
- Glucose intolerance / diabetes: GH antagonizes insulin via IRS-1 serine phosphorylation; patients with insulin resistance, T2DM, or metabolic syndrome at elevated risk
- Compounded product quality: batch-to-batch variability, purity, contamination risks are documented but unquantified [FDA 503A/503B risk documents]
Evidence Gaps (Critical)
| Gap | Detail |
|---|---|
| Combination trials | Zero human trials of the stack for any endpoint |
| Long-term safety | No RCT safety data beyond 49 days for any compound |
| Body composition endpoints | No trial has measured lean mass or fat mass as primary endpoint |
| No-DAC CJC-1295 PK | Commonly cited ~30 min half-life is unverified in primary human literature |
| SC bioavailability | Not reported for either compound in humans |
| Off-label dose efficacy | Human trials used 30–90 µg/kg (~2.1–6.3 mg for 70 kg adult); common off-label 100–300 µg total is far lower with no direct human data |
| Pediatric, elderly, female populations | Not studied |
Best Stack Context
Stack context claims are investigational only — no trial has validated any stack combination for clinical outcomes.
| Adjunct | Rationale | Evidence Level |
|---|---|---|
| BPC-157 | Anabolic recovery; GHR upregulation in preclinical models | Preclinical only; no human evidence for stack interaction |
| GHK-Cu | ECM quality support during GH-driven proliferation | Mechanistic; no human stack data |
| Tesamorelin | Only FDA-approved GHRH analog; clinical body composition data | HIV lipodystrophy indication only; not generalizable to anti-aging |
| Retatrutide | GLP-1/glucagon agonist; lean mass preservation in deficit | GLP-1 class data; no direct stack trial |
Vitals Coaching Guidance (for disclosed users)
If a user and clinician choose this stack, Vitals can support safety monitoring:
- Baseline required: IGF-1, fasting glucose, HbA1c, lipid panel, DEXA (same conditions), ECG (>40 or CV risk)
- Monitoring: IGF-1 every 4–8 weeks; fasting glucose/HbA1c at 4 weeks then every 3 months; BP at each visit
- Target: Maintain IGF-1 within age-adjusted normal range; do not push above upper limit of normal
- Safety gates: Cancer history = contraindication; active malignancy concern = immediate clinician referral; IGF-1 >3× baseline or sustained >ULN = clinician review
- Limitations: Do not interpret changes as proof of efficacy; all monitoring is investigational
Related Notes
- Peptides MOC — peptide hub index
- Tesamorelin — FDA-approved GHRH analog; most comparable secretagogue with clinical body composition data
- GHK-Cu — ECM support during GH-driven repair
- BPC-157 — GHR upregulation in preclinical models; no human stack evidence
- Mitophagy — GH/IGF-1 axis has mitochondrial effects; no direct CJC/Ipa-mitophagy human data
- Retatrutide — GLP-1/glucagon for lean mass preservation; stack combination unstudied
- HRV Guided Training — wearable context for recovery monitoring (not GH-axis specific)
- Sleep Optimization — sleep-HGH physiology context; no direct CJC/Ipa sleep trial
References
| PMID | Study | Key Finding |
|---|---|---|
| [PMID:16352683] | Teichman et al. 2006, J Clin Endocrinol Metab | CJC-1295 DAC: GH 2–10× baseline ≥6 days; IGF-1 1.5–3× baseline 9–11 days; Phase I/II RCT, n=27 |
| [PMID:17018654] | Ionescu & Frohman 2006, J Clin Endocrinol Metab | CJC-1295 DAC: basal/trough GH rose 7.5-fold; pulse frequency/amplitude preserved |
| [PMID:15817669] | CJC-1295 DAC albumin binding | DAC covalently binds albumin at Cys34; half-life ~6–8 days |
| [PMID:19386527] | CJC-1295 biomarker study | Proteome changes 7 days post-dose; systemic downstream consequences |
| [PMID:9849822] | Ipamorelin pharmacology, Eur J Endocrinol | First selective GHS; swine selectivity over ACTH/cortisol at >200× GH ED50 |
| [PMID:10496658] | Ipamorelin PK/PD, Pharm Res | Human IV: t½ ~2h; GH peak at ~0.67h; n=40 healthy males |
| [PMID:25331030] | Ipamorelin Phase II RCT, Int J Colorectal Dis | Postoperative ileus: no significant vs. placebo; program discontinued |
| [PMID:2108187] | GHRH + GHRP synergy, J Clin Endocrinol Metab 1990 | Combined submaximal GHRP + GHRH > either alone in normal men |
| [PMID:11549707] | Ghrelin + GHRH synergy, J Clin Endocrinol Metab 2001 | Ghrelin synergizes with GHRH in humans |
| [PMID:15126555] | GHRP-2 + GHRH in older adults, J Clin Endocrinol Metab 2003 | Combined 24h infusion > monotherapy; sustained pulsatile GH with IGF-1/IGFBP increase |
| [PMID:14576181] | GHSR-1a desensitization, Endocrinology 2003 | Agonist-bound GHSR-1a internalizes via clathrin; slow surface recycling |
| [PMID:8496311] | GHRP tachyphylaxis, J Clin Endocrinol Metab 1993 | Continuous GHRP infusion attenuates subsequent GHRP bolus response in humans |
| [PMID:10990150] | Hexarelin 16-week, J Mol Neurosci 2000 | Reversible partial GH response attenuation at weeks 4 and 16 |
| [PMID:11169166] | GHRH receptor desensitization, Pharmacol Toxicol 2001 | Continuous GHRH exposure causes receptor desensitization in vitro |
| [PMID:9467542] | MK-677 2-month, Clin Endocrinol 1999 | GHS increased GH/IGF-1 in obese subjects; no body composition outcomes |
| [PMID:19174493] | Oral GHS in older adults, J Clin Endocrinol Metab 2008 | Capromorelin: lean mass +1.4 kg vs +0.3 kg placebo; fatigue, insomnia, increased glucose |
| [PMID:18347346] | GH and athletic performance systematic review, Ann Intern Med 2008 | GH in fit adults: +2.1 kg lean mass, no strength/VO2max improvement; edema/fatigue common |
| [PMID:20554713] | Tesamorelin Phase III, J Clin Endocrinol Metab 2010 | VAT −15.4% at 26 weeks; only FDA-approved secretagogue; HIV-specific indication |
| [PMID:37066827] | IGF-1 and mortality, Aging Dis 2023 | U-shaped IGF-1/mortality association; high IGF-1 linked to cancer risk |
| [PMID:21204297] | CJC-1295 identification in black-market preparation | CJC-1295 documented in unknown pharmaceutical preparation |
| WADA 2026 List | S2.2.4 / S2.2.5 | CJC-1295 prohibited (GHRH analogs); Ipamorelin prohibited (GHS) |
⚠️ INVESTIGATIONAL ONLY — NOT FDA APPROVED. Zero human trials of the combination stack for any clinical outcome. All body composition, performance, anti-aging, and recovery claims are extrapolated from individual-component PK/PD data and class-level physiology. Not approved for any clinical indication. WADA-prohibited. Source: BATCH153 canonical monograph, Vitals Research Synthesis, 2026-04-25.